A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD) ? CAPE Save

Date Added
June 16th, 2016
PRO Number
Pro00046546
Researcher
Jose Quiros

List of Studies

Silhouette
Keywords
Bowel, Crohn's Disease, Digestive System, Pediatrics
Summary

A Crohn's Disease Registry for pediatric patients (between the ages of 6 and 17 years) with moderately to severely active Crohn's Disease (CD), who are already taking Humira® (Adalimumab) to treat their condition. Data from the participant's medical record will be collected to study the long-term safety and effectiveness of Humira®. The Registry expects to collect data for 10 years. No study drug will be given.

Institution
MUSC
Recruitment Contact
Kalyan Chundru
843-792-1213
choudhar@musc.edu

Change_preferences

-- OR --

Create_login